[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 2010

Sun, Drugs, and Skin CancerA Continuing Saga

Author Affiliations

Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010

Arch Dermatol. 2010;146(3):329-331. doi:10.1001/archdermatol.2010.25

Photocarcinogenesis continues to be an active field of investigation for dermatologists and photobiologists because of the continuing increased incidence of nonmelanoma skin cancers and of early cutaneous melanomas. Epidemiological and molecular studies provide supporting evidence that solar radiation is a major carcinogen for nonmelanoma skin cancers and melanomas. The wavelengths of UV radiation that reach the surface of the Earth and are able to penetrate skin consist of UV-B (280-315 nm) and UV-A (315-400 nm). Most of the UV radiation that reaches the Earth is UV-A. Only 5% to 10% is in the UV-B range. The major focus of investigations has been UV-B because it is thought to be the more carcinogenic wavelength by virtue of its ability to be directly absorbed by cellular DNA, directly causing damaging mutations in multiple tumor suppressor genes as well as diminishing the skin's immune responses. Mutations induced by UV-B are characterized by the presence of C → T or CC → TT patterns (cyclobutane pyrimidine dimers) and pyrimidine-pyrimidone 6-4 photoproducts (6-4 PP). These are quite specific to damage caused by UV and are referred to as “UV-signature mutations.” 1